Literature DB >> 6652339

In vivo, noradrenaline is a substrate for rat brain monoamine oxidase A and B.

M B Youdim.   

Abstract

In vivo clorgyline (5 mg/kg) and (-)-deprenyl (5 mg/kg) selectively inhibit monoamine oxidase (MAO) type A and B activities in rat brain hypothalamus and caudate nucleus using 5-hydroxytryptamine (5-HT), noradrenaline (NA), and beta-phenylethylamine (PEA) as substrates. Clorgyline induces a significant increase in NA concentrations of hypothalamus and caudate nucleus; however (-)-deprenyl is without effect. The combination of clorgyline and (-)-deprenyl at the above doses completely inhibits both forms of MAO, resulting in an even greater increase in NA levels in both brain areas than observed with clorgyline. The non-selective inhibitor tranylcypromine (5 mg/kg) produced a similar effect. Rats pretreated with the selective or the non-selective inhibitors but given L-DOPA (50 mg/kg) have a similar pattern of brain NA, but its concentrations are higher in both brain regions. The results indicate that although in vitro NA may be an exclusive substrate for MAO type A, in vivo, when this enzyme form is selectively inhibited, NA at high concentrations can be a substrate for MAO type B.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6652339      PMCID: PMC2044871          DOI: 10.1111/j.1476-5381.1983.tb11021.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  8 in total

1.  A SENSITIVE METHOD FOR SPECTROPHOTOFLUOROMETRIC ASSAY OF CATECHOLAMINES.

Authors:  C C CHANG
Journal:  Int J Neuropharmacol       Date:  1964-12

2.  Evidence for dopamine deamination by both type A and type B monoamine oxidase in rat brain in vivo and for the degree of inhibition of enzyme necessary for increased functional activity of dopamine and 5-hydroxytryptamine.

Authors:  A R Green; B D Mitchell; A F Tordoff; M B Youdim
Journal:  Br J Pharmacol       Date:  1977-07       Impact factor: 8.739

3.  Substrate specificity of the different forms of monoamine oxidase in rat liver mitochondria.

Authors:  B Ekstedt
Journal:  Biochem Pharmacol       Date:  1976-05-15       Impact factor: 5.858

4.  The monoamine oxidases of brain: selective inhibition with drugs and the consequences for the metabolism of the biogenic amines.

Authors:  H Y Yang; N H Neff
Journal:  J Pharmacol Exp Ther       Date:  1974-06       Impact factor: 4.030

5.  Evidence for a specific monoamine oxidase associated with sympathetic nerves.

Authors:  C Goridis; N H Neff
Journal:  Neuropharmacology       Date:  1971-09       Impact factor: 5.250

6.  Some observations upon a new inhibitor of monoamine oxidase in brain tissue.

Authors:  J P Johnston
Journal:  Biochem Pharmacol       Date:  1968-07       Impact factor: 5.858

7.  Deamination of 5-hydroxytryptamine by both forms of monoamine oxidase in the rat brain.

Authors:  C J Fowler; K F Tipton
Journal:  J Neurochem       Date:  1982-03       Impact factor: 5.372

8.  Effects of monoamine oxidase inhibition by clorgyline, deprenil or tranylcypromine on 5-hydroxytryptamine concentrations in rat brain and hyperactivity following subsequent tryptophan administration.

Authors:  A R Green; M B Youdim
Journal:  Br J Pharmacol       Date:  1975-11       Impact factor: 8.739

  8 in total
  3 in total

1.  DL-3,4-threo-DOPS in Parkinson's disease: effects on orthostatic hypotension and dizziness.

Authors:  W Birkmayer; G Birkmayer; H Lechner; P Riederer
Journal:  J Neural Transm       Date:  1983       Impact factor: 3.575

Review 2.  Dopamine metabolism and neurotransmission in primate brain in relationship to monoamine oxidase A and B inhibition.

Authors:  M B Youdim; P Riederer
Journal:  J Neural Transm Gen Sect       Date:  1993

3.  Modification of blood pressure and nictitating membrane response to sympathetic amines by selective monoamine oxidase inhibitors, types A and B, in the cat.

Authors:  J P Finberg; M B Youdim
Journal:  Br J Pharmacol       Date:  1985-06       Impact factor: 8.739

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.